CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer
∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics ∙ CureVac RNA Printer...
Vaccine
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...
Humanity Supersedes Technology with Covid Vaccines
Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...
CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...